Search

Your search keyword '"Dearden, Claire"' showing total 813 results
Start Over Author "Dearden, Claire"
813 results on '"Dearden, Claire"'

1. Hairy cell leukemia variant and WHO classification correspondence Re: 5th edition WHO classification haematolymphoid tumors: lymphoid neoplasms

Author

Grever, Michael, Andritsos, Leslie, Anghelina, Mirela, Arons, Evgeny, Banerji, Versha, Barrientos, Jacqueline, Bhat, Seema A., Blachly, James, Broccoli, Alessandro, Call, Timothy, Dearden, Claire, Dietrich, Sascha, Else, Monica, Epperla, Narendranath, Fagarasanu, Andrei, Falini, Brunangelo, Forconi, Francesco, Gozzetti, Alessandro, Hampel, Paul, Hermel, David J., Iyengar, Sunil, Johnston, James B., Juliusson, Gunnar, Kreitman, Robert J., Lauria, Francesco, Lozanski, Gerard, Oakes, Christopher C., Parikh, Sameer A., Park, Jae, Quest, Graeme, Rai, Kanti, Ravandi, Farhad, Robak, Tadeusz, Rogers, Kerry A., Saven, Alan, Seymour, John F., Tadmor, Tamar, Tallman, Martin S., Tam, Constantine S., Tiacci, Enrico, Troussard, Xavier, Wörmann, Bernhard, Zent, Clive S., Zenz, Thorsten, and Zinzani, Pier Luigi

Published
2024
Full Text
View/download PDF

3. Many people with chronic lymphocytic leukemia or small lymphocytic lymphoma benefit from ibrutinib treatment up to 8 years: a plain language summary

Author

Barr, Paul M, Owen, Carolyn, Robak, Tadeusz, Tedeschi, Alessandra, Bairey, Osnat, Burger, Jan A, Hillmen, Peter, Dearden, Claire, Grosicki, Sebastian, McCarthy, Helen, Li, Jian Yong, Offner, Fritz, Moreno, Carol, Jermain, Mandy, Zhou, Cathy, Hsu, Emily, Szoke, Anita, Kipps, Thomas J, and Ghia, Paolo

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Rare Diseases, Cancer, Lymphoma, Clinical Research, Orphan Drug, Hematology, Clinical Trials and Supportive Activities, Lymphatic Research, Good Health and Well Being, chronic lymphocytic leukemia, clinical trial, ibrutinib, lay summary, long-term efficacy, long-term safety, plain language summary, small lymphocytic lymphoma, Oncology and Carcinogenesis, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

What is this summary about?This is a plain language summary of a publication describing long-term results from the RESONATE-2 study with up to 8 years of follow-up. The original paper was published in Blood Advances in June 2022.What were the results?Researchers looked at 269 adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had not received any treatment for their CLL/SLL. Study participants were randomly divided into two groups: 136 participants received treatment with a drug called ibrutinib, and 133 participants received treatment with a drug called chlorambucil. Participants in the study were treated and followed for up to 8 years, with results showing that more participants who took ibrutinib (59%) were alive without worsening of their disease at 7 years after starting treatment than participants who took chlorambucil (9%). Almost half of the participants (42%) were able to stay on ibrutinib treatment for up to 8 years.What do the results of the study mean?In people with CLL or SLL, more participants who were taking ibrutinib were alive without worsening of their disease after 7 years compared with participants who took chlorambucil. Clinical Trial Registration: NCT01722487 (ClinicalTrials.gov) Clinical Trial Registration: NCT01724346 (ClinicalTrials.gov).

Published
2022

4. Up to 8 Years Follow-up From RESONATE-2: First-Line Ibrutinib Treatment for Patients With Chronic Lymphocytic Leukemia

Author

Barr, Paul M, Owen, Carolyn, Robak, Tadeusz, Tedeschi, Alessandra, Bairey, Osnat, Burger, Jan A, Hillmen, Peter, Coutre, Steven E, Dearden, Claire, Grosicki, Sebastian, McCarthy, Helen, Li, Jian-yong, Offner, Fritz, Moreno, Carol, Zhou, Cathy, Hsu, Emily, Szoke, Anita, Kipps, Thomas J, and Ghia, Paolo

Subjects
Lymphoma, Rare Diseases, Clinical Research, Clinical Trials and Supportive Activities, Cancer, Hematology, Orphan Drug, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adenine, Chlorambucil, Follow-Up Studies, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Piperidines, Pyrazoles, Pyrimidines, Treatment Outcome
Abstract

We report long-term follow-up from the RESONATE-2 phase 3 study of the once-daily Bruton's tyrosine kinase inhibitor ibrutinib, which is the only targeted therapy with significant progression-free survival (PFS) and overall survival (OS) benefit in multiple randomized chronic lymphocytic leukemia (CLL) studies. Patients (≥65 years) with previously untreated CLL, without del(17p), were randomly assigned 1:1 to once-daily ibrutinib 420 mg until disease progression/unacceptable toxicity (n = 136) or chlorambucil 0.5-0.8 mg/kg ≤12 cycles (n = 133). With up to 8 years of follow-up (range, 0.1-96.6 months; median, 82.7 months), significant PFS benefit was sustained for ibrutinib vs chlorambucil (hazard ratio [HR], 0.154; 95% confidence interval [CI], 0.108-0.220). At 7 years, PFS was 59% for ibrutinib vs 9% for chlorambucil. PFS benefit was also observed for ibrutinib- vs chlorambucil-randomized patients with high-risk genomic features: del(11q) (HR, 0.033; 95% CI, 0.010-0.107) or unmutated immunoglobulin heavy chain variable region (HR, 0.112; 95% CI, 0.065-0.192). OS at 7 years was 78% with ibrutinib. Prevalence of adverse events (AEs) was consistent with previous 5-year follow-up. Ibrutinib dosing was held (≥7 days) for 79 patients and reduced for 31 patients because of AEs; these AEs resolved or improved in 85% (67 of 79) and 90% (28 of 31) of patients, respectively. With up to 8 years of follow-up, 42% of patients remain on ibrutinib. Long-term RESONATE-2 data demonstrate sustained benefit with first-line ibrutinib treatment for CLL, including for patients with high-risk genomic features. These trials were registered at www.clinicaltrials.gov as #NCT01722487 and #NCT01724346.

Published
2022

5. Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Author

Barrientos, Jacqueline C, O’Brien, Susan, Brown, Jennifer R, Kay, Neil E, Reddy, Nishitha M, Coutre, Steven, Tam, Constantine, Mulligan, Stephen, Jaeger, Ulrich, Devereux, Stephen, Pocock, Christopher, Robak, Tadeusz, Schuster, Stephen J, Schuh, Anna, Gill, Devinder, Bloor, Adrian, Dearden, Claire, Moreno, Carol, Cull, Gavin, Hamblin, Mike, Jones, Jeffrey A, Eckert, Karl, Solman, Isabelle G, Suzuki, Samuel, Hsu, Emily, James, Danelle F, Byrd, John C, and Hillmen, Peter

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Orphan Drug, Lymphoma, Cancer, Clinical Trials and Supportive Activities, Rare Diseases, Clinical Research, Hematology, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Erythrocyte Indices, Female, Follow-Up Studies, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Leukocyte Count, Male, Patient Acceptance of Health Care, Patient Reported Outcome Measures, Quality of Life, Recurrence, Symptom Assessment, Treatment Outcome, Bruton's tyrosine kinase, Disease-related symptoms, Fatigue, Quality of life, Relapsed/refractory CLL/SLL, Clinical Sciences, Cardiovascular medicine and haematology, Oncology and carcinogenesis
Abstract

BackgroundIbrutinib compared with ofatumumab significantly improves progression-free and overall survival in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).Patients and methodsMeasures of well-being were assessed in RESONATE, where previously treated patients with CLL/SLL were randomized to receive ibrutinib 420 mg/day (n = 195) or ofatumumab (n = 196) for up to 24 weeks. Endpoints included hematologic function, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), disease-related symptoms, European Organization for Research and Treatment of Cancer Quality of Life Questionnaires Core 30 (EORTC QLQ-C30), and medical resource utilization.ResultsWith up to 24 months' follow-up (median, 16.4 months), 79% of cytopenic patients showed sustained hematologic improvement (82% with improved platelet count, 69% with improved hemoglobin) on ibrutinib versus 43% on ofatumumab (P < .0001). Higher rates of clinically meaningful improvement were demonstrated with ibrutinib versus ofatumumab for FACIT-F and EORTC global health. Greater improvement was observed in disease-related weight loss, fatigue, night sweats, and abdominal discomfort with ibrutinib versus ofatumumab. Hospitalizations in the first 30 days occurred less frequently with ibrutinib than ofatumumab (0.087 vs. 0.184 events/patient; P = .0198). New-onset diarrhea was infrequent with ibrutinib after the first 6 months (47% at ≤6 months vs. 5% at 12-18 months). With ibrutinib, grade ≥ 3 hypertension occurred in 6%, grade ≥ 3 atrial fibrillation in 4%, major hemorrhage in 2%, and tumor lysis syndrome in 1% of patients.ConclusionIbrutinib led to significant improvements in hematologic function and disease symptomatology versus ofatumumab, and can restore quality of life while prolonging survival in relapsed/refractory CLL/SLL.

Published
2018

6. Patient-driven research: Initial results from a prospective health–related quality of life study performed at the request of patients living with hairy cell leukemia

Author

Anghelina, Mirela, Naughton, Michelle J., Zhao, Qiuhong, Ruppert, Amy S., Neal, Jasmine, Rogers, Kerry A., Blachly, James S., Lozanski, Gerard, Bhat, Seema A., Kraut, Eric, Epperla, Narendranath, Mathur, Puneet, Zent, Clive S., Banerji, Versha, Dearden, Claire, Hutchinson, Terri, Grever, Michael, and Andritsos, Leslie A.

Published
2022
Full Text
View/download PDF

8. Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia

Author

Ravandi, Farhad, Kreitman, Robert J., Tiacci, Enrico, Andritsos, Leslie, Banerji, Versha, Barrientos, Jacqueline C., Bhat, Seema A., Blachly, James S., Broccoli, Alessandro, Call, Timothy, Chihara, Dai, Dearden, Claire, Demeter, Judit, Dietrich, Sasha, Else, Monica, Epperla, Narendranath, Falini, Brunangelo, Forconi, Francesco, Gladstone, Douglas E., Gozzetti, Alessandro, Iyengar, Sunil, Johnston, James B., Jorgensen, Jeffrey, Juliusson, Gunnar, Lauria, Francesco, Lozanski, Gerard, Parikh, Sameer A., Park, Jae H., Polliack, Aaron, Quest, Graeme, Robak, Tadeusz, Rogers, Kerry A., Saven, Alan, Seymour, John F., Tadmor, Tamar, Tallman, Martin S., Tam, Constantine S., Thompson, Philip A., Troussard, Xavier, Zent, Clive S., Zenz, Thorsten, Zinzani, Pier Luigi, Wörmann, Bernhard, Rai, Kanti, and Grever, Michael

Published
2022
Full Text
View/download PDF

9. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia.

Author

Kreitman, Robert, Dearden, Claire, Zinzani, Pier, Delgado, Julio, Karlin, Lionel, Robak, Tadeusz, Gladstone, Douglas, le Coutre, Philipp, Dietrich, Sascha, Gotic, Mirjana, Larratt, Loree, Offner, Fritz, Schiller, Gary, Swords, Ronan, Bacon, Larry, Bocchia, Monica, Bouabdallah, Krimo, Breems, Dimitri, Cortelezzi, Agostino, Dinner, Shira, Doubek, Michael, Gjertsen, Bjorn, Gobbi, Marco, Hellmann, Andrzej, Lepretre, Stephane, Maloisel, Frederic, Ravandi, Farhad, Rousselot, Philippe, Rummel, Mathias, Siddiqi, Tanya, Tadmor, Tamar, Troussard, Xavier, Yi, Cecilia, Saglio, Giuseppe, Roboz, Gail, Balic, Kemal, Standifer, Nathan, He, Peng, Marshall, Shannon, Wilson, Wyndham, Pastan, Ira, Yao, Nai-Shun, and Giles, Francis

Subjects
Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Bacterial Toxins, Drug Resistance, Neoplasm, Exotoxins, Female, Follow-Up Studies, Humans, Leukemia, Hairy Cell, Male, Middle Aged, Neoplasm Recurrence, Local, Prognosis, Remission Induction, Salvage Therapy, Survival Rate
Abstract

This is a pivotal, multicenter, open-label study of moxetumomab pasudotox, a recombinant CD22-targeting immunotoxin, in hairy cell leukemia (HCL), a rare B cell malignancy with high CD22 expression. The study enrolled patients with relapsed/refractory HCL who had ≥2 prior systemic therapies, including ≥1 purine nucleoside analog. Patients received moxetumomab pasudotox 40 µg/kg intravenously on days 1, 3, and 5 every 28 days for ≤6 cycles. Blinded independent central review determined disease response and minimal residual disease (MRD) status. Among 80 patients (79% males; median age, 60.0 years), durable complete response (CR) rate was 30%, CR rate was 41%, and objective response rate (CR and partial response) was 75%; 64 patients (80%) achieved hematologic remission. Among complete responders, 27 (85%) achieved MRD negativity by immunohistochemistry. The most frequent adverse events (AEs) were peripheral edema (39%), nausea (35%), fatigue (34%), and headache (33%). Treatment-related serious AEs of hemolytic uremic syndrome (7.5%) and capillary leak syndrome (5%) were reversible and generally manageable with supportive care and treatment discontinuation (6 patients; 7.5%). Moxetumomab pasudotox treatment achieved a high rate of independently assessed durable response and MRD eradication in heavily pretreated patients with HCL, with acceptable tolerability.

Published
2018

10. Hairy cell leukemia and COVID-19 adaptation of treatment guidelines

Author

Grever, Michael, Andritsos, Leslie, Banerji, Versha, Barrientos, Jacqueline C., Bhat, Seema, Blachly, James S., Call, Timothy, Cross, Matthew, Dearden, Claire, Demeter, Judit, Dietrich, Sasha, Falini, Brunangelo, Forconi, Francesco, Gladstone, Douglas E., Gozzetti, Alessandro, Iyengar, Sunil, Johnston, James B., Juliusson, Gunnar, Kraut, Eric, Kreitman, Robert J., Lauria, Francesco, Lozanski, Gerard, Parikh, Sameer A., Park, Jae, Polliack, Aaron, Ravandi, Farhad, Robak, Tadeusz, Rogers, Kerry A., Saven, Alan, Seymour, John F., Tadmor, Tamar, Tallman, Martin S., Tam, Constantine S., Tiacci, Enrico, Troussard, Xavier, Zent, Clive, Zenz, Thorsten, Zinzani, Pier Luigi, and Wörmann, Bernhard

Published
2021
Full Text
View/download PDF

11. Prolymphocytic Leukaemia

Author

Dearden, Claire, Dreyling, Martin, Series Editor, Hallek, Michael, editor, Eichhorst, Barbara, editor, and Catovsky, Daniel, editor

Published
2019
Full Text
View/download PDF

12. Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study

Author

Herling, Marco, primary, Dearden, Claire, additional, Zaja, Francesco, additional, El-Sharkawi, Dima, additional, Ding, Wei, additional, Bellido, Mar, additional, Khot, Amit, additional, Tick, Lidwine, additional, Jacobsen, Eric, additional, Eyre, Toby A., additional, Roos-Weil, Damien, additional, Kadia, Tapan, additional, Lucchini, Elisa, additional, Pflug, Natali, additional, Davids, Matthew S., additional, Pena, German, additional, Mukherjee, Nabanita, additional, Badawi, Mohamed, additional, Vizkelety, Tamas, additional, and Staber, Philipp B., additional

Published
2024
Full Text
View/download PDF

14. Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia

Author

Staber, Philipp B., Herling, Marco, Bellido, Mar, Jacobsen, Eric D., Davids, Matthew S., Kadia, Tapan Mahendra, Shustov, Andrei, Tournilhac, Olivier, Bachy, Emmanuel, Zaja, Francesco, Porkka, Kimmo, Hoermann, Gregor, Simonitsch-Klupp, Ingrid, Haferlach, Claudia, Kubicek, Stefan, Mayerhoefer, Marius E., Hopfinger, Georg, Jaeger, Ulrich, and Dearden, Claire

Published
2019
Full Text
View/download PDF

15. Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

Author

Byrd, John C, Brown, Jennifer R, O'Brien, Susan, Barrientos, Jacqueline C, Kay, Neil E, Reddy, Nishitha M, Coutre, Steven, Tam, Constantine S, Mulligan, Stephen P, Jaeger, Ulrich, Devereux, Steve, Barr, Paul M, Furman, Richard R, Kipps, Thomas J, Cymbalista, Florence, Pocock, Christopher, Thornton, Patrick, Caligaris-Cappio, Federico, Robak, Tadeusz, Delgado, Julio, Schuster, Stephen J, Montillo, Marco, Schuh, Anna, de Vos, Sven, Gill, Devinder, Bloor, Adrian, Dearden, Claire, Moreno, Carol, Jones, Jeffrey J, Chu, Alvina D, Fardis, Maria, McGreivy, Jesse, Clow, Fong, James, Danelle F, and Hillmen, Peter

Subjects
Lymphoma, Rare Diseases, Orphan Drug, Clinical Research, Hematology, Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adenine, Adult, Agammaglobulinaemia Tyrosine Kinase, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Cough, Diarrhea, Disease-Free Survival, Fatigue, Female, Follow-Up Studies, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Male, Middle Aged, Piperidines, Protein-Tyrosine Kinases, Pyrazoles, Pyrimidines, Recurrence, Survival Rate, RESONATE Investigators, Medical and Health Sciences, General & Internal Medicine
Abstract

BackgroundIn patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL), a short duration of response to therapy or adverse cytogenetic abnormalities are associated with a poor outcome. We evaluated the efficacy of ibrutinib, a covalent inhibitor of Bruton's tyrosine kinase, in patients at risk for a poor outcome.MethodsIn this multicenter, open-label, phase 3 study, we randomly assigned 391 patients with relapsed or refractory CLL or SLL to receive daily ibrutinib or the anti-CD20 antibody ofatumumab. The primary end point was the duration of progression-free survival, with the duration of overall survival and the overall response rate as secondary end points.ResultsAt a median follow-up of 9.4 months, ibrutinib significantly improved progression-free survival; the median duration was not reached in the ibrutinib group (with a rate of progression-free survival of 88% at 6 months), as compared with a median of 8.1 months in the ofatumumab group (hazard ratio for progression or death in the ibrutinib group, 0.22; P

Published
2014

18. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL

Author

Barr, Paul M., Brown, Jennifer R., Hillmen, Peter, O'Brien, Susan, Barrientos, Jacqueline C., Reddy, Nishitha M., Coutre, Steven, Mulligan, Stephen P., Jaeger, Ulrich, Furman, Richard R., Cymbalista, Florence, Montillo, Marco, Dearden, Claire, Robak, Tadeusz, Moreno, Carol, Pagel, John M., Burger, Jan A., Suzuki, Samuel, Sukbuntherng, Juthamas, Cole, George, James, Danelle F., and Byrd, John C.

Published
2017
Full Text
View/download PDF

20. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

Author

Grever, Michael R., Abdel-Wahab, Omar, Andritsos, Leslie A., Banerji, Versha, Barrientos, Jacqueline, Blachly, James S., Call, Timothy G., Catovsky, Daniel, Dearden, Claire, Demeter, Judit, Else, Monica, Forconi, Francesco, Gozzetti, Alessandro, Ho, Anthony D., Johnston, James B., Jones, Jeffrey, Juliusson, Gunnar, Kraut, Eric, Kreitman, Robert J., Larratt, Loree, Lauria, Francesco, Lozanski, Gerard, Montserrat, Emili, Parikh, Sameer A., Park, Jae H., Polliack, Aaron, Quest, Graeme R., Rai, Kanti R., Ravandi, Farhad, Robak, Tadeusz, Saven, Alan, Seymour, John F., Tadmor, Tamar, Tallman, Martin S., Tam, Constantine, Tiacci, Enrico, Troussard, Xavier, Zent, Clive S., Zenz, Thorsten, Zinzani, Pier Luigi, and Falini, Brunangelo

Published
2017
Full Text
View/download PDF

22. Hairy cell leukemia variant and WHO classification correspondence Re: 5thedition WHO classification haematolymphoid tumors: lymphoid neoplasms

Author

Grever, Michael, Andritsos, Leslie, Anghelina, Mirela, Arons, Evgeny, Banerji, Versha, Barrientos, Jacqueline, Bhat, Seema A., Blachly, James, Broccoli, Alessandro, Call, Timothy, Dearden, Claire, Dietrich, Sascha, Else, Monica, Epperla, Narendranath, Fagarasanu, Andrei, Falini, Brunangelo, Forconi, Francesco, Gozzetti, Alessandro, Hampel, Paul, Hermel, David J., Iyengar, Sunil, Johnston, James B., Juliusson, Gunnar, Kreitman, Robert J., Lauria, Francesco, Lozanski, Gerard, Oakes, Christopher C., Parikh, Sameer A., Park, Jae, Quest, Graeme, Rai, Kanti, Ravandi, Farhad, Robak, Tadeusz, Rogers, Kerry A., Saven, Alan, Seymour, John F., Tadmor, Tamar, Tallman, Martin S., Tam, Constantine S., Tiacci, Enrico, Troussard, Xavier, Wörmann, Bernhard, Zent, Clive S., Zenz, Thorsten, and Zinzani, Pier Luigi

Published
2024
Full Text
View/download PDF

23. Supplementary Figure 1 from Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing

Author

Parry, Marina, primary, Rose-Zerilli, Matthew J.J., primary, Ljungström, Viktor, primary, Gibson, Jane, primary, Wang, Jun, primary, Walewska, Renata, primary, Parker, Helen, primary, Parker, Anton, primary, Davis, Zadie, primary, Gardiner, Anne, primary, McIver-Brown, Neil, primary, Kalpadakis, Christina, primary, Xochelli, Aliki, primary, Anagnostopoulos, Achilles, primary, Fazi, Claudia, primary, Gonzalez de Castro, David, primary, Dearden, Claire, primary, Pratt, Guy, primary, Rosenquist, Richard, primary, Ashton-Key, Margaret, primary, Forconi, Francesco, primary, Collins, Andrew, primary, Ghia, Paolo, primary, Matutes, Estella, primary, Pangalis, Gerassimos, primary, Stamatopoulos, Kostas, primary, Oscier, David, primary, and Strefford, Jonathan C., primary

Published
2023
Full Text
View/download PDF

24. Supplementary Table 4 from Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing

Author

Parry, Marina, primary, Rose-Zerilli, Matthew J.J., primary, Ljungström, Viktor, primary, Gibson, Jane, primary, Wang, Jun, primary, Walewska, Renata, primary, Parker, Helen, primary, Parker, Anton, primary, Davis, Zadie, primary, Gardiner, Anne, primary, McIver-Brown, Neil, primary, Kalpadakis, Christina, primary, Xochelli, Aliki, primary, Anagnostopoulos, Achilles, primary, Fazi, Claudia, primary, Gonzalez de Castro, David, primary, Dearden, Claire, primary, Pratt, Guy, primary, Rosenquist, Richard, primary, Ashton-Key, Margaret, primary, Forconi, Francesco, primary, Collins, Andrew, primary, Ghia, Paolo, primary, Matutes, Estella, primary, Pangalis, Gerassimos, primary, Stamatopoulos, Kostas, primary, Oscier, David, primary, and Strefford, Jonathan C., primary

Published
2023
Full Text
View/download PDF

25. Supplementary Figure 2 from Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing

Author

Parry, Marina, primary, Rose-Zerilli, Matthew J.J., primary, Ljungström, Viktor, primary, Gibson, Jane, primary, Wang, Jun, primary, Walewska, Renata, primary, Parker, Helen, primary, Parker, Anton, primary, Davis, Zadie, primary, Gardiner, Anne, primary, McIver-Brown, Neil, primary, Kalpadakis, Christina, primary, Xochelli, Aliki, primary, Anagnostopoulos, Achilles, primary, Fazi, Claudia, primary, Gonzalez de Castro, David, primary, Dearden, Claire, primary, Pratt, Guy, primary, Rosenquist, Richard, primary, Ashton-Key, Margaret, primary, Forconi, Francesco, primary, Collins, Andrew, primary, Ghia, Paolo, primary, Matutes, Estella, primary, Pangalis, Gerassimos, primary, Stamatopoulos, Kostas, primary, Oscier, David, primary, and Strefford, Jonathan C., primary

Published
2023
Full Text
View/download PDF

26. Supplementary Tables 1-3 from Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing

Author

Parry, Marina, primary, Rose-Zerilli, Matthew J.J., primary, Ljungström, Viktor, primary, Gibson, Jane, primary, Wang, Jun, primary, Walewska, Renata, primary, Parker, Helen, primary, Parker, Anton, primary, Davis, Zadie, primary, Gardiner, Anne, primary, McIver-Brown, Neil, primary, Kalpadakis, Christina, primary, Xochelli, Aliki, primary, Anagnostopoulos, Achilles, primary, Fazi, Claudia, primary, Gonzalez de Castro, David, primary, Dearden, Claire, primary, Pratt, Guy, primary, Rosenquist, Richard, primary, Ashton-Key, Margaret, primary, Forconi, Francesco, primary, Collins, Andrew, primary, Ghia, Paolo, primary, Matutes, Estella, primary, Pangalis, Gerassimos, primary, Stamatopoulos, Kostas, primary, Oscier, David, primary, and Strefford, Jonathan C., primary

Published
2023
Full Text
View/download PDF

27. Supplementary Table 6 from Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing

Author

Parry, Marina, primary, Rose-Zerilli, Matthew J.J., primary, Ljungström, Viktor, primary, Gibson, Jane, primary, Wang, Jun, primary, Walewska, Renata, primary, Parker, Helen, primary, Parker, Anton, primary, Davis, Zadie, primary, Gardiner, Anne, primary, McIver-Brown, Neil, primary, Kalpadakis, Christina, primary, Xochelli, Aliki, primary, Anagnostopoulos, Achilles, primary, Fazi, Claudia, primary, Gonzalez de Castro, David, primary, Dearden, Claire, primary, Pratt, Guy, primary, Rosenquist, Richard, primary, Ashton-Key, Margaret, primary, Forconi, Francesco, primary, Collins, Andrew, primary, Ghia, Paolo, primary, Matutes, Estella, primary, Pangalis, Gerassimos, primary, Stamatopoulos, Kostas, primary, Oscier, David, primary, and Strefford, Jonathan C., primary

Published
2023
Full Text
View/download PDF

28. Supplementary Table 5 from Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing

Author

Parry, Marina, primary, Rose-Zerilli, Matthew J.J., primary, Ljungström, Viktor, primary, Gibson, Jane, primary, Wang, Jun, primary, Walewska, Renata, primary, Parker, Helen, primary, Parker, Anton, primary, Davis, Zadie, primary, Gardiner, Anne, primary, McIver-Brown, Neil, primary, Kalpadakis, Christina, primary, Xochelli, Aliki, primary, Anagnostopoulos, Achilles, primary, Fazi, Claudia, primary, Gonzalez de Castro, David, primary, Dearden, Claire, primary, Pratt, Guy, primary, Rosenquist, Richard, primary, Ashton-Key, Margaret, primary, Forconi, Francesco, primary, Collins, Andrew, primary, Ghia, Paolo, primary, Matutes, Estella, primary, Pangalis, Gerassimos, primary, Stamatopoulos, Kostas, primary, Oscier, David, primary, and Strefford, Jonathan C., primary

Published
2023
Full Text
View/download PDF

29. Supplementary Figures 1-3, Tables 1-3 from Functional Analysis of the ATM-p53-p21 Pathway in the LRF CLL4 Trial: Blockade at the Level of p21 Is Associated with Short Response Duration

Author

Lin, Ke, primary, Adamson, Janet, primary, Johnson, Gillian G., primary, Carter, Anthony, primary, Oates, Melanie, primary, Wade, Rachel, primary, Richards, Sue, primary, Gonzalez, David, primary, Matutes, Estella, primary, Dearden, Claire, primary, Oscier, David G., primary, Catovsky, Daniel, primary, and Pettitt, Andrew R., primary

Published
2023
Full Text
View/download PDF

30. Supplementary Table 7 from Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing

Author

Parry, Marina, primary, Rose-Zerilli, Matthew J.J., primary, Ljungström, Viktor, primary, Gibson, Jane, primary, Wang, Jun, primary, Walewska, Renata, primary, Parker, Helen, primary, Parker, Anton, primary, Davis, Zadie, primary, Gardiner, Anne, primary, McIver-Brown, Neil, primary, Kalpadakis, Christina, primary, Xochelli, Aliki, primary, Anagnostopoulos, Achilles, primary, Fazi, Claudia, primary, Gonzalez de Castro, David, primary, Dearden, Claire, primary, Pratt, Guy, primary, Rosenquist, Richard, primary, Ashton-Key, Margaret, primary, Forconi, Francesco, primary, Collins, Andrew, primary, Ghia, Paolo, primary, Matutes, Estella, primary, Pangalis, Gerassimos, primary, Stamatopoulos, Kostas, primary, Oscier, David, primary, and Strefford, Jonathan C., primary

Published
2023
Full Text
View/download PDF

32. BRAF inhibition in hairy cell leukemia with low-dose vemurafenib

Author

Dietrich, Sascha, Pircher, Andreas, Endris, Volker, Peyrade, Frédéric, Wendtner, Clemens-Martin, Follows, George A., Hüllein, Jennifer, Jethwa, Alexander, Ellert, Elena, Walther, Tatjana, Liu, Xiyang, Dyer, Martin J.S., Elter, Thomas, Brummer, Tilman, Zeiser, Robert, Hermann, Michael, Herold, Michael, Weichert, Wilko, Dearden, Claire, Haferlach, Torsten, Seiffert, Martina, Hallek, Michael, von Kalle, Christof, Ho, Anthony D., Gaehler, Anita, Andrulis, Mindaugas, Steurer, Michael, and Zenz, Thorsten

Published
2016
Full Text
View/download PDF

33. Correlation of T‐cell receptor constant beta‐chain 1 by flow cytometry with molecular T‐cell receptor clonality for the investigation of T‐cell lymphoproliferation.

Author

Dexter, Tania, Taiwo, Tosin, Dearden, Claire, Chan, Li Yuan, Taussig, David, El‐Sharkawi, Dima, Dunlop, Alan, and Iyengar, Sunil

Subjects
T cells, FLOW cytometry, CLONE cells, T cell receptors
Abstract

The article discusses the use of T-cell receptor constant beta-chain 1 (TRBC1) expression as a marker for T-cell clonality in the diagnosis of T-cell lymphomas. The study compared TRBC1 testing with genetic studies and found that TRBC1 expression detected by flow cytometry showed 100% concordance with genetic testing for T-cell clonality. The authors concluded that TRBC1 testing, along with immunophenotyping, could replace genetic testing in cases where an abnormal T-cell phenotype is detected or when flow cytometry is inconclusive. The study was supported by the National Institute for Health Research and the authors declared no conflicts of interest. [Extracted from the article]

Published
2024
Full Text
View/download PDF

35. Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology

Author

Went, Molly, Sud, Amit, Speedy, Helen, Sunter, Nicola J., Försti, Asta, Law, Philip J., Johnson, David C., Mirabella, Fabio, Holroyd, Amy, Li, Ni, Orlando, Giulia, Weinhold, Niels, van Duin, Mark, Chen, Bowang, Mitchell, Jonathan S., Mansouri, Larry, Juliusson, Gunnar, Smedby, Karin E, Jayne, Sandrine, Majid, Aneela, Dearden, Claire, Allsup, David J., Bailey, James R., Pratt, Guy, Pepper, Chris, Fegan, Chris, Rosenquist, Richard, Kuiper, Rowan, Stephens, Owen W., Bertsch, Uta, Broderick, Peter, Einsele, Hermann, Gregory, Walter M., Hillengass, Jens, Hoffmann, Per, Jackson, Graham H., Jöckel, Karl-Heinz, Nickel, Jolanta, Nöthen, Markus M., da Silva Filho, Miguel Inacio, Thomsen, Hauke, Walker, Brian A., Broyl, Annemiek, Davies, Faith E., Hansson, Markus, Goldschmidt, Hartmut, Dyer, Martin J. S., Kaiser, Martin, Sonneveld, Pieter, Morgan, Gareth J., Hemminki, Kari, Nilsson, Björn, Catovsky, Daniel, Allan, James M., and Houlston, Richard S.

Published
2019
Full Text
View/download PDF

38. Autologous Transplantation in First Remission in the Rituximab Era in Patients with Mantle Cell Lymphoma: Experience from the Royal Marsden Hospital

Author

Mir, Farheen, primary, Robinson, Anna, additional, Ethell, Mark Edward, additional, Potter, Michael, additional, Nicholson, Emma, additional, Anthias, Chloe, additional, Easdale, Sandra, additional, Gonzalez-Arias, Carlos, additional, Sud, Amit, additional, Dearden, Claire E., additional, Chau, Ian, additional, Cunningham, David, additional, El-Sharkawi, Dima, additional, Sharma, Bhupinder, additional, and Iyengar, Sunil, additional

Published
2022
Full Text
View/download PDF

40. Corrigendum to “Patient-driven research: Initial results from a prospective health–related quality of life study performed at the request of patients living with hairy cell leukemia” [Leuk. Res. 120 (2022) 106919]

Author

Anghelina, Mirela, primary, Naughton, Michelle J., additional, Zhao, Qiuhong, additional, Ruppert, Amy S., additional, Neal, Jasmine, additional, Rogers, Kerry A., additional, Blachly, James S., additional, Lozanski, Gerard, additional, Bhat, Seema A., additional, Kraut, Eric, additional, Epperla, Narendranath, additional, Mathur, Puneet, additional, Zent, Clive S., additional, Banerji, Versha, additional, Dearden, Claire, additional, Hutchinson, Terri, additional, Grever, Michael, additional, and Andritsos, Leslie A., additional

Published
2022
Full Text
View/download PDF

41. Development of a distributed international patient data registry for hairy cell leukemia

Author

Andritsos, Leslie A., primary, Anghelina, Mirela, additional, Neal, Jasmine, additional, Blachly, James S., additional, Mathur, Puneet, additional, Lele, Omkar, additional, Dearden, Claire, additional, Iyengar, Sunil, additional, Cross, Matthew, additional, Zent, Clive S., additional, Rogers, Kerry A., additional, Epperla, Narendranath, additional, Lozanski, Gerard, additional, Oakes, Christopher C., additional, Kraut, Eric, additional, Ruppert, Amy S., additional, Zhao, Qiuhong, additional, Bhat, Seema A., additional, Forconi, Francesco, additional, Banerji, Versha, additional, Handunnetti, Sasanka, additional, Tam, Constantine S., additional, Seymour, John F., additional, Else, Monica, additional, Kreitman, Robert J., additional, Saven, Alan, additional, Call, Timothy, additional, Parikh, Sameer A., additional, Ravandi, Farhad, additional, Johnston, James B., additional, Tiacci, Enrico, additional, Troussard, Xavier, additional, Tallman, Martin S., additional, Dietrich, Sascha, additional, Tadmor, Tamar, additional, Gozzetti, Alessandro, additional, Zinzani, Pier Luigi, additional, Robak, Tadeusz, additional, Quest, Graeme, additional, Demeter, Judit, additional, Rai, Kanti, additional, Fernandez, Soledad A., additional, and Grever, Michael, additional

Published
2022
Full Text
View/download PDF

42. A 3-decade multicenter European experience with cladribine as upfront treatment in 384 hairy cell leukemia patients

Author

Broccoli, Alessandro, Argnani, Lisa, Cross, Matthew, Janus, Agnieszka, Maitre, Elsa, Troussard, Xavier, Robak, Tadeusz, Dearden, Claire, Else, Monica, Catovsky, Daniel, Zinzani, Pier Luigi, Broccoli, Alessandro, Argnani, Lisa, Cross, Matthew, Janus, Agnieszka, Maitre, Elsa, Troussard, Xavier, Robak, Tadeusz, Dearden, Claire, Else, Monica, Catovsky, Daniel, and Zinzani, Pier Luigi

Subjects
Cladribine, up-front treatment, hairy cell leukemia
Abstract

Cladribine is regarded as the first treatment of choice of symptomatic hairy cell leukemia (HCL): it provides high rates of response and very long duration of remission in some cases. Disease-specific patients records have been reviewed at four European centers of excellence; all patients with HCL requiring treatment who received frontline cladribine have been extrapolated. Responses have been classified according to Consensus Resolution Criteria. Three hundred and eighty-four patients have been diagnosed and followed between 1969 and 2018; all received frontline cladribine (subcutaneously or intravenously). A complete response was obtained in 72% of cases and a partial response in 22%. A continuous complete response was documented in 20% of patients at a median follow-up period of 8.5 years (range, 1-22 years). Median overall survival was reached at 25 years. Median progression-free survival was 13 years and median disease-free survival was 11 years. Cladribine is effective as frontline treatment of HCL and may determine deep disease control in a significant proportion of cases, given that more than 50% of treated patients require no further therapy. Good quality responses may be maintained for more than 20 years in up to 35% of patients.

Published
2022

47. Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation

Author

Michallet, Mauricette, Dreger, Peter, Sutton, Laurent, Brand, Ronald, Richards, Sue, van Os, Marleen, Sobh, Mohamad, Choquet, Sylvain, Corront, Bernadette, Dearden, Claire, Gratwohl, Alois, Herr, Wolfgang, Catovsky, Daniel, Hallek, Michael, de Witte, Theo, Niederwieser, Dietger, Leporrier, Michel, and Milligan, Donald

Published
2011
Full Text
View/download PDF

48. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia

Author

Barr, Paul M., Owen, Carolyn, Robak, Tadeusz, Tedeschi, Alessandra, Bairey, Osnat, Burger, Jan A, Hillmen, Peter, Coutre, Steve E., Dearden, Claire, Grosicki, Sebastian, McCarthy, Helen, Li, Jian-Yong, Offner, Fritz, Moreno, Carol, Zhou, Ccathy, Hsu, Emily, Szoke, Anita, Kipps, Thomas J., Ghia, Paolo, and Universitat Autònoma de Barcelona

Subjects
Leukemia, Lymphoma, Adenine, Clinical Trials and Supportive Activities, B-Cell, Hematology, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphocytic, Orphan Drug, Rare Diseases, Pyrimidines, Treatment Outcome, Piperidines, Clinical Research, 6.1 Pharmaceuticals, Medicine and Health Sciences, Humans, Pyrazoles, Chlorambucil, RITUXIMAB, Chronic, Cancer, Follow-Up Studies
Abstract

We report long-term follow-up from the RESONATE-2 phase 3 study of the once-daily Bruton’s tyrosine kinase inhibitor ibrutinib, which is the only targeted therapy with significant progression-free survival (PFS) and overall survival (OS) benefit in multiple randomized chronic lymphocytic leukemia (CLL) studies. Patients (≥65 years) with previously untreated CLL, without del(17p), were randomly assigned 1:1 to once-daily ibrutinib 420 mg until disease progression/unacceptable toxicity (n = 136) or chlorambucil 0.5-0.8 mg/kg ≤12 cycles (n = 133). With up to 8 years of follow-up (range, 0.1-96.6 months; median, 82.7 months), significant PFS benefit was sustained for ibrutinib vs chlorambucil (hazard ratio [HR], 0.154; 95% confidence interval [CI], 0.108-0.220). At 7 years, PFS was 59% for ibrutinib vs 9% for chlorambucil. PFS benefit was also observed for ibrutinib- vs chlorambucil-randomized patients with high-risk genomic features: del(11q) (HR, 0.033; 95% CI, 0.010-0.107) or unmutated immunoglobulin heavy chain variable region (HR, 0.112; 95% CI, 0.065-0.192). OS at 7 years was 78% with ibrutinib. Prevalence of adverse events (AEs) was consistent with previous 5-year follow-up. Ibrutinib dosing was held (≥7 days) for 79 patients and reduced for 31 patients because of AEs; these AEs resolved or improved in 85% (67 of 79) and 90% (28 of 31) of patients, respectively. With up to 8 years of follow-up, 42% of patients remain on ibrutinib. Long-term RESONATE-2 data demonstrate sustained benefit with first-line ibrutinib treatment for CLL, including for patients with high-risk genomic features. These trials were registered at www.clinicaltrials.gov as #NCT01722487 and #NCT01724346.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results